Clinical trials: Upper Cross Syndrome
- Condition Upper Cross Syndrome
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy
A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC Interval
The purpose of this study is to assess the electrocardiogram (ECG) effects of fedovapagon dose administration relative to placebo in healthy adult male and female subjects.
- Trial name
- NCT02537288
- Testing
- Fedovapagon, Moxifloxacin
- Where
- Germany
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Vantia Ltd
Amputation of Hip and Thigh, Level Unspecified
Assessment of Disability Compensation With the C-LEG COMPACT 2 Knee (Ref. 3C60 et 3C60=ST)
Moderately active amputees may have lost their limb due to diabetes, vascular conditions, trauma, tumour or congenital causes. These amputees currently cannot benefit from having a computerised knee because of the performance…
- Trial name
- NCT02382991
- Testing
- 3C60-NMPK, NMPK-3C60
- Where
- 15 sites in Austria, France and 1 more
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Otto Bock France SNC
COVID-19
Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine
This is a phase Ⅳ follow-up clinical trial based on the previous Phase Ⅳ clinical trial of an inactivated COVID-19 vaccine (CoronaVac) manufactured by Sinovac Life Sciences Co., Ltd.The purpose of this study is to evaluate the…
- Trial name
- NCT05329038
- Testing
- Inactivated COVID-19 Vaccine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Healthy
Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals
Assess the electrocardiogram effects of TRV130 relative to placebo at therapeutic and supratherapeutic doses.
- Trial name
- NCT02344303
- Testing
- TRV130, Moxifloxacin
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Trevena Inc.